Verteporfin photodynamic therapy in the age of antiangiogenic therapy

References

• Klein R, Klein BE, Linton KL; The Beaver Dam Eye Study. Prevalence of age-related maculopathy. Ophthalmology99(6), 933–943 (1992).
   PubMed Web of Science ®Google Scholar
• Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv. Ophthalmol.32(6), 375–413 (1988).
   PubMed Web of Science ®Google Scholar
• Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol.100(6), 912–918 (1982).
   PubMed Web of Science ®Google Scholar
• Mennel S, Barbazetto I, Meyer CH, Peter S, Stur M. Ocular photodynamic therapy – standard applications and new indications (part 1). Review of the literature and personal experience. Ophthalmologica221(4), 216–226 (2007).
   PubMed Web of Science ®Google Scholar
• Raab O. Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Z. Biol.39, 524–546 (1900).
   Google Scholar
• Von Tappeiner HAAJ. Die sensibilisierende wirkung fluorieszierender substanzer. gesammte untersuchungen uber die photodynamische erscheinung. FCW Vogel, Leipzig, Germany (1907).
   Google Scholar
• Hausmann W. Die sensibilisierende wirkung des hematoporphyrins. Biochem. Z.30, 276–316 (1911).
   Google Scholar
• Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv. Ophthalmol.45(3), 195–214 (2000).
   PubMed Web of Science ®Google Scholar
• Royster AJ, Nanda SK, Hatchell DL, Tiedeman JS, Dutton JJ, Hatchell MC. Photochemical initiation of thrombosis. Fluorescein angiographic, histologic, and ultrastructural alterations in the choroid, retinal pigment epithelium, and retina. Arch. Ophthalmol.106(11), 1608–1614 (1988).
   PubMedGoogle Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials – TAP report. Treatment of Age-related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Arch. Ophthalmol.117(10), 1329–1345 (1999).
   PubMed Web of Science ®Google Scholar
• Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial – VIP report no. 1. Ophthalmology108(5), 841–852 (2001).
   PubMed Web of Science ®Google Scholar
• Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch. Ophthalmol.119(2), 198–207 (2001).
   PubMed Web of Science ®Google Scholar
• Sanchez MC, Barcelona PF, Luna JD et al. Low-density lipoprotein receptor-related protein-1 (LRP-1) expression in a rat model of oxygen-induced retinal neovascularization. Exp. Eye Res.83(6), 1378–1385 (2006).
   PubMed Web of Science ®Google Scholar
• Noske UM, Schmidt-Erfurth U, Meyer C, Diddens H. Lipid metabolism in retinal pigment epithelium. Possible significance of lipoprotein receptors. Ophthalmologe95(12), 814–819 (1998).
   PubMed Web of Science ®Google Scholar
• Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr.16(4), 279–305 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T, Gragoudas E, Michaud N, Flotte TJ, Birngruber R. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology101(12), 1953–1961 (1994).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Michels S, Indorf L, Eggers R, Birngruber R. Mechanism of photodynamic occlusion using liposomal Zn(II)-phtalocyanine. Curr. Eye Res.30(7), 601–612 (2005).
   PubMed Web of Science ®Google Scholar
• Fingar VH. Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg.14(5), 323–328 (1996).
   PubMedGoogle Scholar
• Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina22(1), 6–18 (2002).
   PubMed Web of Science ®Google Scholar
• Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina25(2), 119–134 (2005).
   PubMed Web of Science ®Google Scholar
• Blumenkranz MS, Bressler NM, Bressler SB et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: three-year results of an open-label extension of 2 randomized clinical trials – TAP Report no. 5. Arch. Ophthalmol.120(10), 1307–1314 (2002).
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: 5-year results of two randomized clinical trials with an open-label extension: TAP report no. 8. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(9), 1132–1142 (2006).
   Google Scholar
• Rubin GS, Bressler NM. Effects of verteporfin therapy on contrast on sensitivity: results from the treatment of age-related macular degeneration with photodynamic therapy (TAP) investigation-TAP report No 4. Retina22(5), 536–544 (2002).
   PubMed Web of Science ®Google Scholar
• Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization – verteporfin in photodynamic therapy report 2. Am. J. Ophthalmol.131(5), 541–560 (2001).
   PubMed Web of Science ®Google Scholar
• Hayashi K, Ohno-Matsui K, Teramukai S et al. Photodynamic therapy with verteporfin for choroidal neovascularization of pathologic myopia in Japanese patients: comparison with nontreated controls. Am. J. Ophthalmol.145(3), 518–526 (2008).
   PubMed Web of Science ®Google Scholar
• Lam DS, Liu DT, Fan DS, Lai WW, So SF, Chan WM. Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia-1-year results of a prospective series. Eye19(8), 834–840 (2005).
   PubMed Web of Science ®Google Scholar
• Ohno-Matsui K, Yoshida T. Myopic choroidal neovascularization: natural course and treatment. Curr. Opin. Ophthalmol.15(3), 197–202 (2004).
   PubMedGoogle Scholar
• Pece A, Isola V, Vadala M, Matranga D. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to pathologic myopia: long-term study. Retina26(7), 746–751 (2006).
   PubMed Web of Science ®Google Scholar
• Azab M, Boyer DS, Bressler NM et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch. Ophthalmol.123(4), 448–457 (2005).
   PubMed Web of Science ®Google Scholar
• Wormald R, Evans J, Smeeth L, Henshaw K. Photodynamic therapy for neovascular age-related macular degeneration. Cochrane Database Syst. Rev.3, CD002030 (2007).
   PubMedGoogle Scholar
• Michels S, Wachtlin J, Gamulescu MA et al. Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. Ophthalmology112(12), 2070–2075 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Saperstein DA, Bressler NM et al. Photodynamic therapy with verteporfin in ocular histoplasmosis: uncontrolled, open-label 2-year study. Ophthalmology111(9), 1725–1733 (2004).
   PubMed Web of Science ®Google Scholar
• Mennel S, Barbazetto I, Meyer CH, Peter S, Stur M. Ocular photodynamic therapy – standard applications and new indications (part 2). Review of the literature and personal experience. Ophthalmologica. Journal international d’ophtalmologie. Int. J. Ophthalmol.221(5), 282–291 (2007).
   Google Scholar
• Chan WM, Lam DS, Lai TY et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology111(8), 1576–1584 (2004).
   PubMed Web of Science ®Google Scholar
• Lee SC, Seong YS, Kim SS, Koh HJ, Kwon OW. Photodynamic therapy with verteporfin for polypoidal choroidal vasculopathy of the macula. Ophthalmologica. Journal international d’ophtalmologie. Int. J. Ophthalmol.218(3), 193–201 (2004).
   Google Scholar
• Ojima Y, Tsujikawa A, Otani A, Hirami Y, Aikawa H, Yoshimura N. Recurrent bleeding after photodynamic therapy in polypoidal choroidal vasculopathy. Am. J. Ophthalmol.141(5), 958–960 (2006).
   PubMed Web of Science ®Google Scholar
• Quaranta M, Mauget-Faysse M, Coscas G. Exudative idiopathic polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Am. J. Ophthalmol.134(2), 277–280 (2002).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Donsoff I, Lam DL et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy. Retina22(5), 529–535 (2002).
   PubMed Web of Science ®Google Scholar
• Kusserow C, Michels S, Schmidt-Erfurth U. Chorioretinal anastomosis as unfavourable prognostic factor during photodynamic therapy. Ophthalmologe100(3), 197–202 (2003).
   PubMed Web of Science ®Google Scholar
• Boscia F, Parodi MB, Furino C, Reibaldi M, Sborgia C. Photodynamic therapy with verteporfin for retinal angiomatous proliferation. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(10), 1224–1232 (2006).
   Google Scholar
• Gross NE, Aizman A, Brucker A, Klancnik JM Jr, Yannuzzi LA. Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation. Retina25(6), 713–718 (2005).
   PubMed Web of Science ®Google Scholar
• Hunter MA, Dunbar MT, Rosenfeld PJ. Retinal angiomatous proliferation: clinical characteristics and treatment options. Optometry75(9), 577–588 (2004).
   PubMedGoogle Scholar
• Krebs I, Stolba U, Glittenberg C, Seyeddain O, Benesch T, Binder S. Prognosis of untreated occult choroidal neovascularization. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol. (2006).
   Google Scholar
• Kuerzinger GR, Lang GK, Lang GE. Retinal angiomatous proliferation in age-related macular degeneration. Klin. Monatsbl. Augenheilkd223(8), 691–695 (2006).
   PubMed Web of Science ®Google Scholar
• Bottoni F, Massacesi A, Cigada M, Viola F, Musicco I, Staurenghi G. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. Arch. Ophthalmol.123(12), 1644–1650 (2005).
   PubMed Web of Science ®Google Scholar
• Krebs I, Binder S, Stolba U. A new treatment regimen in combined intravitreal injection of triamcinolone acetonide and photodynamic therapy. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(7), 863–867 (2006).
   Google Scholar
• Mantel I, Ambresin A, Zografos L. Retinal angiomatous proliferation treated with a combination of intravitreal triamcinolone acetonide and photodynamic therapy with verteporfin. Eur. J. Ophthalmol.16(5), 705–710 (2006).
   PubMed Web of Science ®Google Scholar
• Nicolo M, Ghiglione D, Lai S, Calabria G. Retinal angiomatous proliferation treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Graefe’s archive for clinical and experimental ophthalmology Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(10), 1336–1338 (2006).
   Google Scholar
• Salazar-Diez JL, Iturralde-Errea D, Diaz-de-Durana-Santacoloma E, Fernandez-Ares ML, Vazquez-Cruchaga E, Lopez-Garrido JA. Results of treatment of retinal angiomatous proliferation with photodynamic therapy. Arch. Soc. Esp. Oftalmol.81(7), 401–404 (2006).
   PubMedGoogle Scholar
• Sutter FK, Kurz-Levin MM, Fleischhauer J, Bosch MM, Barthelmes D, Helbig H. Macular atrophy after combined intravitreal triamcinolone acetonide (IVTA) and photodynamic therapy (PDT) for retinal angiomatous proliferation (RAP). Klin. Monatsbl. Augenheilkd223(5), 376–378 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Martin ML, Slakter J et al. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am. J. Ophthalmol.134(1), 62–68 (2002).
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Wehner A, Heimann H, Foerster MH. Photodynamic treatment with verteporfin for patients with idiopathic choroidal neovascularization. Two-year results. Ophthalmologe101(5), 489–495 (2004).
   PubMed Web of Science ®Google Scholar
• Yoo MH, Boo HD, Kim HK. Result of photodynamic therapy for idiopathic subfoveal choroidal neovascularization. Korean J. Ophthalmol.19(4), 264–268 (2005).
   PubMedGoogle Scholar
• Chan WM, Lam DS, Wong TH et al. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology110(12), 2395–2402 (2003).
   PubMed Web of Science ®Google Scholar
• Lam A, Lee HC, Ho AC, Regillo CD, McNamara JA, Fineman MD. Photodynamic therapy in young patients. Ophthalmic. Surg. Lasers Imaging.37(3), 182–189 (2006).
   PubMed Web of Science ®Google Scholar
• Muller-Velten R, Michels S, Schmidt-Erfurth U, Laqua H. Photodynamic therapy: extended indication. Ophthalmologe100(5), 384–390 (2003).
   PubMed Web of Science ®Google Scholar
• Mauget-Faysse M, Mimoun G, Ruiz-Moreno JM et al. Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Retina26(4), 396–403 (2006).
   PubMed Web of Science ®Google Scholar
• Nessi F, Guex-Crosier Y, Ambresin A, Zografos L. Photodynamic therapy with verteporfin for subfoveal choroidal neovascularization secondary to toxoplasmic chorioretinal scar. Klin. Monatsbl. Augenheilkd.221(5), 371–373 (2004).
   PubMed Web of Science ®Google Scholar
• Oliveira LB, Reis PA. Photodynamic therapy-treated choroidal neovascular membrane secondary to toxoplasmic retinochoroiditis. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.242(12), 1028–1030 (2004).
   Google Scholar
• Wirthlin R, Song A, Song J, Rosenfeld PJ. Verteporfin photodynamic therapy of choroidal neovascularization secondary to ocular toxoplasmosis. Arch. Ophthalmol.124(5), 741–743 (2006).
   PubMedGoogle Scholar
• Postelmans L, Pasteels B, Coquelet P et al. Photodynamic therapy for subfoveal classic choroidal neovascularization related to punctate inner choroidopathy (PIC) or presumed ocular histoplasmosis-like syndrome (POHS-like). Occul. Immunol. Inflamm.13(5), 361–366 (2005).
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Heimann H, Behme T, Foerster MH. Long-term results after photodynamic therapy with verteporfin for choroidal neovascularizations secondary to inflammatory chorioretinal diseases. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.241(11), 899–906 (2003).
   Google Scholar
• Coquelet P, Postelmans L, Snyers B, Verougstraete C. Successful photodynamic therapy combined with laser photocoagulation in three eyes with classic subfoveal choroidal neovascularisation affecting two patients with multifocal choroiditis: case reports. Bull. Soc. Belge. Ophtalmol.283, 69–73 (2002).
   Google Scholar
• Gerth C, Spital G, Lommatzsch A, Heiligenhaus A, Pauleikhoff D. Photodynamic therapy for choroidal neovascularization in patients with multifocal choroiditis and panuveitis. Eur. J. Ophthalmol.16(1), 111–118 (2006).
   PubMed Web of Science ®Google Scholar
• Kertes PJ, Coupland SG. The use of subretinal triamcinolone acetonide in the management of neovascular age-related macular degeneration: a pilot study. Can. J. Ophthalmol.40(5), 573–584 (2005).
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P, Spasse S, Ravalico G. Photodynamic therapy for juxtafoveal choroidal neovascularization associated with multifocal choroiditis. Am. J. Ophthalmol.141(1), 123–128 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Freund KB, Slakter J, Sorenson J, Yannuzzi LA, Fisher Y. Treatment of subfoveal choroidal neovascularization associated with multifocal choroiditis and panuveitis with photodynamic therapy. Retina22(5), 545–549 (2002).
   PubMed Web of Science ®Google Scholar
• Sickenberg M, Schmidt-Erfurth U, Miller JW et al. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes. Arch. Ophthalmol.118(3), 327–336 (2000).
   PubMedGoogle Scholar
• Arias L, Pujol O, Rubio M, Caminal J. Long-term results of photodynamic therapy for the treatment of choroidal neovascularization secondary to angioid streaks. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(6), 753–757 (2006).
   Google Scholar
• Browning AC, Chung AK, Ghanchi F et al. Verteporfin photodynamic therapy of choroidal neovascularization in angioid streaks: one-year results of a prospective case series. Ophthalmology112(7), 1227–1231 (2005).
   PubMed Web of Science ®Google Scholar
• Heimann H, Gelisken F, Wachtlin J et al. Photodynamic therapy with verteporfin for choroidal neovascularization associated with angioid streaks. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.243(11), 1115–1123 (2005).
   Google Scholar
• Jurklies B, Bornfeld N, Schilling H. Photodynamic therapy using verteporfin for choroidal neovascularization associated with angioid streaks – long-term effects. Ophthalmic. Res.38(4), 209–217 (2006).
   PubMed Web of Science ®Google Scholar
• Ladas ID, Georgalas I, Rouvas AA, Gotsis S, Karagiannis DA, Moschos M. Photodynamic therapy with verteporfin of choroidal neovascularization in angioid streaks: conventional versus early retreatment. Eur. J. Ophthalmol.15(1), 69–73 (2005).
   PubMed Web of Science ®Google Scholar
• Conrath J, Forzano O, Ridings B. Photodynamic therapy for subfoveal CNV complicating traumatic choroidal rupture. Eye18(9), 946–947 (2004).
   PubMed Web of Science ®Google Scholar
• Mehta HB, Shanmugam MP. Photodynamic therapy of a posttraumatic choroidal neovascular membrane. Indian J. Ophthalmol.53(2), 131–132 (2005).
   PubMedGoogle Scholar
• Sobaci G, Bayraktar MZ, Karslioglu Y, Durukan AH, Hurmeric V, Aykas S. Hypericin-enhanced argon laser photocoagulation for subfoveal choroidal neovascular membrane in age-related macular degeneration: a pilot study. Eur. J. Ophthalmol.16(1), 119–128 (2006).
   Web of Science ®Google Scholar
• Harissi-Dagher M, Sebag M, Gauthier D, Marcil G, Labelle P, Arbour JD. Photodynamic therapy in young patients with choroidal neovascularization following traumatic choroidal rupture. Am. J. Ophthalmol.139(4), 726–728 (2005).
   PubMed Web of Science ®Google Scholar
• Souied EH, Pawlak D, Algan M, Sayag D, Coscas G, Soubrane G. Photodynamic therapy for choroidal neovascularization on late-onset fundus flavimaculatus. Am. J. Ophthalmol.140(2), 312–314 (2005).
   PubMed Web of Science ®Google Scholar
• Valmaggia C, Niederberger H, Helbig H. Photodynamic therapy for choroidal neovascularization in fundus flavimaculatus. Retina22(1), 111–113 (2002).
   PubMed Web of Science ®Google Scholar
• Battaglia Parodi M, Da Pozzo S, Ravalico G. Photodynamic therapy for choroidal neovascularization associated with pattern dystrophy. Retina23(2), 171–176 (2003).
   PubMed Web of Science ®Google Scholar
• Ergun E, Costa D, Slakter J, Yannuzzi LA, Stur M. Photodynamic therapy and vitelliform lesions. Retina24(3), 399–406 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenblatt BJ, Shah GK, Blinder K. Photodynamic therapy with verteporfin for peripapillary choroidal neovascularization. Retina25(1), 33–37 (2005).
   PubMed Web of Science ®Google Scholar
• Palumbo G. Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin. Drug Deliv.4(2), 131–148 (2007).
   PubMed Web of Science ®Google Scholar
• Barbazetto I, Schmidt-Erfurth U. Photodynamic therapy of choroidal hemangioma: two case reports. Graefe’s archive for clinical and experimental ophthalmology. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.238(3), 214–221 (2000).
   Google Scholar
• Robertson DM. Photodynamic therapy for choroidal hemangioma associated with serous retinal detachment. Arch. Ophthalmol.120(9), 1155–1161 (2002).
   PubMedGoogle Scholar
• Schmidt-Erfurth UM, Michels S, Kusserow C, Jurklies B, Augustin AJ. Photodynamic therapy for symptomatic choroidal hemangioma: visual and anatomic results. Ophthalmology109(12), 2284–2294 (2002).
   PubMed Web of Science ®Google Scholar
• Shields JA, Shields CL, Materin MA, Marr BP, Demirci H, Mashayekhi A. Changing concepts in management of circumscribed choroidal hemangioma: the 2003 J. Howard Stokes Lecture, Part 1. Ophthalmic. Surg. Lasers Imaging.35(5), 383–394 (2004).
   PubMedGoogle Scholar
• Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology109(7), 1256–1266 (2002).
   PubMed Web of Science ®Google Scholar
• Aaberg TM Jr, Aaberg TM Sr, Martin DF, Gilman JP, Myles R. Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy. Arch. Ophthalmol.123(3), 328–332 (2005).
   PubMedGoogle Scholar
• Atebara NH. Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am. J. Ophthalmol.134(5), 788–790 (2002).
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Sears JE, Singh AD. Transient closure of a retinal capillary hemangioma with verteporfin photodynamic therapy. Retina25(8), 1103–1104 (2005).
   PubMed Web of Science ®Google Scholar
• Golshevsky JR, O’Day J. Photodynamic therapy in the management of juxtapapillary capillary haemangiomas. Clin. Exp. Ophthalmol.33(5), 509–512 (2005).
   PubMed Web of Science ®Google Scholar
• Barbazetto IA, Smith RT. Vasoproliferative tumor of the retima treated with PDT. Retina23(4), 565–567 (2003).
   PubMed Web of Science ®Google Scholar
• Blasi MA, Scupola A, Tiberti AC, Sasso P, Balestrazzi E. Photodynamic therapy for vasoproliferative retinal tumors. Retina26(4), 404–409 (2006).
   PubMed Web of Science ®Google Scholar
• Javellana JA, Drouilhet JH, Kokame GT, Chee PH, Wong BM. Retinal capillary angioma in familial exudative vitreoretinopathy treated with photodynamic therapy. Am. J. Ophthalmol.137(4), 780–782 (2004).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Coleman H, Spaide RF, Yannuzzi LA. Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina22(2), 228–232 (2002).
   PubMed Web of Science ®Google Scholar
• Barbazetto IA, Lee TC, Rollins IS, Chang S, Abramson DH. Treatment of choroidal melanoma using photodynamic therapy. Am. J. Ophthalmol.135(6), 898–899 (2003).
   PubMed Web of Science ®Google Scholar
• Donaldson MJ, Lim L, Harper CA, Mackenzie J, G Campbell W. Primary treatment of choroidal amelanotic melanoma with photodynamic therapy. Clin. Exp. Ophthalmol.33(5), 548–549 (2005).
   PubMed Web of Science ®Google Scholar
• Foster BS, Gragoudas ES, Young LH. Photodynamic therapy of choroidal melanoma. Int. Ophthalmol. Clin.37(4), 117–126 (1997).
   PubMedGoogle Scholar
• Gonzalez VH, Hu LK, Theodossiadis PG, Flotte TJ, Gragoudas ES, Young LH. Photodynamic therapy of pigmented choroidal melanomas. Invest. Opthalmol. Vis. Sci.36(5), 871–878 (1995).
   PubMed Web of Science ®Google Scholar
• Hu L, Wu X, Song Y, Young LH, Gragoudas ES. Photodynamic therapy of pigmented choroidal melanomas in rabbits. Zhonghua yan ke za zhi. Chinese J. Ophthalmol.38(8), 491–494 (2002).
   PubMedGoogle Scholar
• Kim RY, Hu LK, Flotte TJ, Gragoudas ES, Young LH. Digital angiography of experimental choroidal melanomas using benzoporphyrin derivative. Am. J. Ophthalmol.123(6), 810–816 (1997).
   PubMed Web of Science ®Google Scholar
• Kim RY, Hu LK, Foster BS, Gragoudas ES, Young LH. Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness. Ophthalmology103(12), 2029–2036 (1996).
   PubMed Web of Science ®Google Scholar
• Young LH, Howard MA, Hu LK, Kim RY, Gragoudas ES. Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch. Ophthalmol.114(2), 186–192 (1996).
   PubMed Web of Science ®Google Scholar
• Barbazetto IA, Lee TC, Abramson DH. Treatment of conjunctival squamous cell carcinoma with photodynamic therapy. Am. J. Ophthalmol.138(2), 183–189 (2004).
   PubMed Web of Science ®Google Scholar
• Procianoy F, Cruz AA, Baccega A, Ferraz V, Chahud F. Aggravation of eyelid and conjunctival malignancies following photodynamic therapy in DeSanctis-Cacchione syndrome. Ophthalmic Plast. Reconstr. Surg.22(6), 498–499 (2006).
   PubMed Web of Science ®Google Scholar
• Fossarello M, Peiretti E, Zucca I, Perra MT, Serra A. Photodynamic therapy of pterygium with verteporfin: a preliminary report. Cornea23(4), 330–338 (2004).
   PubMed Web of Science ®Google Scholar
• Valmaggia C, Niederberger H. Photodynamic therapy in the treatment of chronic central serous chorioretinopathy. Klin. Monatsbl. Augenheilkd.223(5), 372–375 (2006).
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA, Slakter JS, Gross NE et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. Retina23(3), 288–298 (2003).
   PubMed Web of Science ®Google Scholar
• Canakis C, Livir-Rallatos C, Panayiotis Z et al. Ocular photodynamic therapy for serous macular detachment in the diffuse retinal pigment epitheliopathy variant of idiopathic central serous chorioretinopathy. Am. J. Ophthalmol.136(4), 750–752 (2003).
   PubMed Web of Science ®Google Scholar
• Cardillo Piccolino F, Eandi CM, Ventre L, Rigault de la Longrais RC, Grignolo FM. Photodynamic therapy for chronic central serous chorioretinopathy. Retina23(6), 752–763 (2003).
   PubMed Web of Science ®Google Scholar
• Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br. J. Ophthalmol.87(12), 1453–1458 (2003).
   PubMed Web of Science ®Google Scholar
• Ober MD, Yannuzzi LA, Do DV et al. Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology112(12), 2088–2094 (2005).
   PubMed Web of Science ®Google Scholar
• Lai TY, Chan WM, Li H, Lai RY, Liu DT, Lam DS. Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br. J. Ophthalmol.90(7), 869–874 (2006).
   PubMed Web of Science ®Google Scholar
• Stewart JM. Half dose verteporfin PDT for central serous chorioretinopathy. Br. J. Ophthalmol.90(7), 805–806 (2006).
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, Lam DS. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina28(1), 85–93 (2008).
   PubMed Web of Science ®Google Scholar
• Mennel S, Hoerle S, Meyer CH. Photodynamic therapy in symptomatic parafoveal telangiectasia secondary to Osler–Rendu–Weber disease. Acta Ophthalmol. Scand.84(2), 273–275 (2006).
   PubMedGoogle Scholar
• De Lahitte GD, Cohen SY, Gaudric A. Lack of apparent short-term benefit of photodynamic therapy in bilateral, acquired, parafoveal telangiectasis without subretinal neovascularization. Am. J. Ophthalmol.138(5), 892–894 (2004).
   PubMed Web of Science ®Google Scholar
• Shanmugam MP, Agarwal M. RPE atrophy following photodynamic therapy in type 2A idiopathic parafoveal telangiectasis. Indian J. Ophthalmol.53(1), 61–63 (2005).
   PubMedGoogle Scholar
• Fossarello M, Peiretti E, Zucca I, Serra A. Photodynamic therapy of corneal neovascularization with verteporfin. Cornea22(5), 485–488 (2003).
   PubMed Web of Science ®Google Scholar
• Muller VA, Ruokonen P, Schellenbeck M, Hartmann C, Tetz M. Treatment of rubeosis iridis with photodynamic therapy with verteporfin – a new therapeutic and prophylactic option for patients with the risk of neovascular glaucoma? Ophthalmic. Res.35(1), 60–64 (2003).
   PubMed Web of Science ®Google Scholar
• Parodi MB, Iacono P. Photodynamic therapy with verteporfin for anterior segment neovascularizations in neovascular glaucoma. Am. J. Ophthalmol.138(1), 157–158 (2004).
   PubMed Web of Science ®Google Scholar
• Davidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single bevacizumab (Avastin) injection. Retina26(3), 354–356 (2006).
   PubMed Web of Science ®Google Scholar
• Grisanti S, Biester S, Peters S, Tatar O, Ziemssen F, Bartz-Schmidt KU. Intracameral bevacizumab for iris rubeosis. Am. J. Ophthalmol.142(1), 158–160 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Schlotzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest. Opthalmol. Vis. Sci.44(10), 4473–4480 (2003).
   PubMed Web of Science ®Google Scholar
• Michels S, Schmidt-Erfurth U. Sequence of early vascular events after photodynamic therapy. Invest. Opthalmol. Vis. Sci.44(5), 2147–2154 (2003).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology112(12), 2061–2069 (2005).
   PubMed Web of Science ®Google Scholar
• Kaiser PK. Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration. Curr. Med. Res. Opin.23(3), 477–487 (2007).
   PubMed Web of Science ®Google Scholar
• Folkman J, Ingber DE. Angiostatic steroids. Method of discovery and mechanism of action. Ann. Surg.206(3), 374–383 (1987).
   PubMed Web of Science ®Google Scholar
• Penfold PL, Wen L, Madigan MC, King NJ, Provis JM. Modulation of permeability and adhesion molecule expression by human choroidal endothelial cells. Invest. Opthalmol. Vis. Sci.43(9), 3125–3130 (2002).
   PubMed Web of Science ®Google Scholar
• Penfold PL, Wong JG, Gyory J, Billson FA. Effects of triamcinolone acetonide on microglial morphology and quantitative expression of MHC-II in exudative age-related macular degeneration. Clin. Exp. Ophthalmol.29(3), 188–192 (2001).
   PubMed Web of Science ®Google Scholar
• Wang YS, Friedrichs U, Eichler W, Hoffmann S, Wiedemann P. Inhibitory effects of triamcinolone acetonide on bFGF-induced migration and tube formation in choroidal microvascular endothelial cells. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.240(1), 42–48 (2002).
   Google Scholar
• Jonas JB. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic. Res.38(4), 218–245 (2006).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmology110(8), 1517–1525 (2003).
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy and triamcinolone acetonide: convergent modes of action for treatment of neovascular age-related macular degeneration. Eur. J. Ophthalmol.16(6), 824–834 (2006).
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol.141(4), 638–645 (2006).
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology113(1), 14–22 (2006).
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Wong AL, Tong JP, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of subfoveal choroidal neovascularisation in age related macular degeneration: a comparative study. Br. J. Ophthalmol.90(3), 337–341 (2006).
   PubMed Web of Science ®Google Scholar
• Fackler TK, Reddy S, Bearelly S, Stinnett S, Fekrat S, Cooney MJ. Retrospective review of eyes with neovascular age-related macular degeneration treated with photodynamic therapy with verteporfin and intravitreal triamcinolone. Ann. Acad. Med. Singap.35(10), 701–705 (2006).
   PubMed Web of Science ®Google Scholar
• Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am. J. Ophthalmol.142(2), 335–337 (2006).
   PubMed Web of Science ®Google Scholar
• Nicolo M, Ghiglione D, Lai S, Nasciuti F, Cicinelli S, Calabria G. Occult with no classic choroidal neovascularization secondary to age-related macular degeneration treated by intravitreal triamcinolone and photodynamic therapy with verteporfin. Retina26(1), 58–64 (2006).
   PubMed Web of Science ®Google Scholar
• Peiretti E, Klancnik JM Jr, Spaide RF, Yannuzzi L. Choroidal neovascularization in sorsby fundus dystrophy treated with photodynamic therapy and intravitreal triamcinolone acetonide. Retina25(3), 377–379 (2005).
   PubMed Web of Science ®Google Scholar
• Potter MJ, Szabo SM, Ho T. Combined photodynamic therapy and intravitreal triamcinolone for the treatment of myopic choroidal neovascularization in a 13-year-old girl. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(5), 639–641 (2006).
   Google Scholar
• Rechtman E, Danis RP, Pratt LM, Harris A. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularisation in age related macular degeneration. Br. J. Ophthalmol.88(3), 344–347 (2004).
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Barile S. Triamcinolone and PDT to treat exudative age-related macular degeneration and submacular hemorrhage. Eur. J. Ophthalmol.16(3), 426–434 (2006).
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina26(6), 602–612 (2006).
   PubMed Web of Science ®Google Scholar
• Smithen LM, Spaide RF. Photodynamic therapy and intravitreal triamcinolone for a subretinal neovascularization in bilateral idiopathic juxtafoveal telangiectasis. Am. J. Ophthalmol.138(5), 884–885 (2004).
   PubMed Web of Science ®Google Scholar
• Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology112(2), 301–304 (2005).
   PubMed Web of Science ®Google Scholar
• Axer-Siegel R, Ehrlich R, Avisar I et al. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment. Ophthalmic. Surg. Lasers Imaging.37(6), 455–461 (2006).
   PubMedGoogle Scholar
• Ergun E, Maar N, Ansari-Shahrezaei S et al. Photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide in the treatment of neovascular age-related macular degeneration. Am. J. Ophthalmol.142(1), 10–16 (2006).
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br. J. Ophthalmol.91(2), 174–179 (2007).
   PubMed Web of Science ®Google Scholar
• Jonas JB, Degenring RF, Kreissig I, Akkoyun I, Kamppeter BA. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology112(4), 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina27(2), 133–140 (2007).
   PubMed Web of Science ®Google Scholar
• Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina25(2), 111–118 (2005).
   PubMed Web of Science ®Google Scholar
• Gaudreault J, Fei D, Rusit J, Suboc P, Shiu V. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Opthalmol. Vis. Sci.46(2), 726–733 (2005).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. New Engl. J. Med.351(27), 2805–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Kaiser PK VSG. Verteporfin therapy in combination with pegaptanib or triamcinolone for wet AMD: 6-month results of the VERITAS trial. Invest. Ophthalmol. Vis. Sci. Fort Lauderdale, FL, USA. ARVO e-abstract number 2870 (2007).
   Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. New Engl. J. Med.355(14), 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Rich RM, Lalwani GA. Ranibizumab: Phase III clinical trial results. Ophthalmol. Clin. N. Am.19(3), 361–372 (2006).
   PubMedGoogle Scholar
• Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. New Engl. J. Med.355(14), 1432–1444 (2006).
   PubMed Web of Science ®Google Scholar
• Fung AE, Rosenfeld PJ, Reichel E. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br. J. Ophthalmol.90(11), 1344–1349 (2006).
   PubMed Web of Science ®Google Scholar
• Geitzenauer W, Michels S, Prager F et al. Early effects of systemic and intravitreal bevacizumab (avastin) therapy for neovascular age-related macular degeneration. Klin. Monatsbl. Augenheilkd.223(10), 822–827 (2006).
   PubMed Web of Science ®Google Scholar
• Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology112(6), 1035–1047 (2005).
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology113(11), e2001–e2012 (2006).
   Google Scholar
• Rich RM, Rosenfeld PJ, Puliafito CA et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina26(5), 495–511 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ. Intravitreal Avastin for choroidal neovascularisation in pathological myopia: the controversy continues. Br. J. Ophthalmol.91(2), 128–130 (2007).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ. Intravitreal avastin: the low cost alternative to lucentis? Am. J. Ophthalmol.142(1), 141–143 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Fung AE, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusion. Ophthalmic. Surg. Lasers Imaging.36(4), 336–339 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging.36(4), 331–335 (2005).
   PubMed Web of Science ®Google Scholar
• Craig M, Greven M, Winston-Salem NC et al. AMD and VEGF: Where do we go from here? Rev. Ophthalmol.14, 2 (2007).
   Google Scholar
• Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc. Natl Acad. Sci. USA104(3), 967–972 (2007).
   PubMed Web of Science ®Google Scholar
• Costa RA, Jorge R, Calucci D, Melo LA Jr, Cardillo JA, Scott IU. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study). Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.245(9), 1273–1280 (2007).
   Google Scholar
• Dhalla MS, Shah GK, Blinder KJ, Ryan EH Jr, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina26(9), 988–993 (2006).
   PubMed Web of Science ®Google Scholar
• Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina26(9), 994–998 (2006).
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology114(6), 1179–1185 (2007).
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N, Dekaris I, Gavric M, Bosnar D. Photodynamic therapy combined with intravitreal bevacizumab (Avastin) in treatment of choroidal neovascularization secondary to age-related macular degeneration. Collegium Antropologicum31(Suppl. 1), 71–75 (2007).
   PubMedGoogle Scholar
• Schmidt-Erfurth AA, Georgopoulos M, Kiss C et al. Antiangiogenesis in neovascular macular degeneration: new therapeutical strategies. Spektrum Augenheilkd19, 317–325 (2005).
   Google Scholar
• Weigert G, Michels S, Sacu S et al. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. Br. J. Ophthalmol.92(3), 356–360 (2008).
   PubMed Web of Science ®Google Scholar
• Azab M, Benchaboune M, Blinder KJ et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials: Treatment Of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy Study Report no. 4. Retina24(1), 1–12 (2004).
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology110(4), 667–673 (2003).
   PubMed Web of Science ®Google Scholar
• Arnold JJ, Blinder KJ, Bressler NM et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials – TAP and VIP report no. 3. Am. J. Ophthalmol.137(4), 683–696 (2004).
   PubMed Web of Science ®Google Scholar
• Gelisken F, Inhoffen W, Partsch M, Schneider U, Kreissig I. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am. J. Ophthalmol.131(4), 518–520 (2001).
   PubMed Web of Science ®Google Scholar
• Goldstein M, Heilweil G, Barak A, Loewenstein A. Retinal pigment epithelial tear following photodynamic therapy for choroidal neovascularization secondary to AMD. Eye19(12), 1315–1324 (2005).
   PubMed Web of Science ®Google Scholar
• Pece A, Introini U, Bottoni F, Brancato R. Acute retinal pigment epithelial tear after photodynamic therapy. Retina21(6), 661–665 (2001).
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Sternberg P Jr. Retinal pigment epithelial tear weeks following photodynamic therapy with verteporfin for choroidal neovascularization secondary to pathologic myopia. Retina22(5), 669–671 (2002).
   PubMed Web of Science ®Google Scholar
• Chaudhry NA, Lavaque AJ, Tom DE, Liggett PE. Large submacular hemorrhage following PDT with verteporfin in patients with occult CNVM secondary to age-related macular degeneration. Ophthalmic. Surg. Lasers Imaging38(1), 64–68 (2007).
   PubMedGoogle Scholar
• Do DV, Bressler NM, Bressler SB. Large submacular hemorrhages after verteporfin therapy. Am. J. Ophthalmol.137(3), 558–560 (2004).
   PubMed Web of Science ®Google Scholar
• Ladas ID, Moschos MM, Rouvas AA, Karagiannis DA, Kokolakis SN. Lacquer crack formation after photodynamic therapy. Eur. J. Ophthalmol.13(8), 729–733 (2003).
   PubMed Web of Science ®Google Scholar
• Holz ER, Linares L, Mieler WF, Weinberg DV. Exudative complications after photodynamic therapy. Arch. Ophthalmol.121(11), 1649–1652 (2003).
   PubMedGoogle Scholar
• Mennel S, Meyer CH, Eggarter F, Peter S. Transient serous retinal detachment in classic and occult choroidal neovascularization after photodynamic therapy. Am. J. Ophthalmol.140(4), 758–760 (2005).
   PubMed Web of Science ®Google Scholar
• Ratanasukon M, Wongchaikunakorn N. Exudative retinal detachment after photodynamic therapy: a case report in an Asian patient. Eye20(4), 499–502 (2006).
   PubMed Web of Science ®Google Scholar
• Rumelt S, Kaiserman I, Rehany U, Ophir A, Pikkel J, Loewenstein A. Detachment of subfoveal choroidal neovascularization in age-related macular degeneration. Am. J. Ophthalmol.134(6), 822–827 (2002).
   PubMed Web of Science ®Google Scholar
• Battaglia Parodi M, Da Pozzo S, Ravalico G. Retinal pigment epithelium changes after photodynamic therapy for choroidal neovascularization in pathological myopia. Acta Ophthalmol. Scand.85(1), 50–54 (2007).
   PubMedGoogle Scholar
• Glacet-Bernard A, Coscas G, Soubrane G. Pigment epithelial changes in young women treated with photodynamic therapy and limited macular translocation for classic choroidal neovascularisation. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.244(10), 1373–1376 (2006).
   Google Scholar
• Postelmans L, Pasteels B, Coquelet P, El Ouardighi H, Verougstraete C, Schmidt-Erfurth U. Severe pigment epithelial alterations in the treatment area following photodynamic therapy for classic choroidal neovascularization in young females. Am. J. Ophthalmol.138(5), 803–808 (2004).
   PubMed Web of Science ®Google Scholar
• Diaz M, Cervera E, Hernandez M, Salom D. Abnormal response of the retinal pigment epithelium to photodynamic therapy in a child. Retina26(7), 834–836 (2006).
   PubMed Web of Science ®Google Scholar
• Sii F, Lee LR. Retinopathy associated with photodynamic therapy for treatment of idiopathic choroidal neovascularization. Clin. Exp. Ophthalmol.34(2), 184–186 (2006).
   PubMed Web of Science ®Google Scholar
• Giansanti F, Virgili G, Varano M et al. Photodynamic therapy for choroidal neovascularization in pediatric patients. Retina25(5), 590–596 (2005).
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Behme T, Heimann H, Kellner U, Foerster MH. Concentric retinal pigment epithelium atrophy after a single photodynamic therapy. Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.241(6), 518–521 (2003).
   Google Scholar
• Singh AD, Rundle PA, Vardy SJ, Rennie IG. Photodynamic therapy of choroidal haemangioma associated with Sturge-Weber syndrome. Eye19(3), 365–367 (2005).
   PubMed Web of Science ®Google Scholar
• Zarbin M. Should corticosteroids be considered as part of the standard care with photodynamic therapy? Arch. Ophthalmol.124(4), 563–571 (2006).
   PubMedGoogle Scholar
• Degenring RF, Jonas JB. Photodynamic therapy in combination with intravitreal triamcinolone for myopic choroidal neovascularization. Acta Ophthalmol. Scand.83(5), 621 (2005).
   PubMedGoogle Scholar
• Blaha GR, Wertz FD 3rd, Marx JL. Profound choroidal hypoperfusion after combined photodynamic therapy and intravitreal triamcinolone acetonide. Ophthalmic. Surg. Lasers Imaging39(1), 6–11 (2008).
   PubMedGoogle Scholar
• Wu L, Martinez-Castellanos MA, Quiroz-Mercado H et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): results of the Pan-American Collaborative Retina Study Group (PACORES). Albrecht Von Graefes Arch. Klin. Exp. Ophthalmol.246(1), 81–87 (2008).
   Google Scholar
• D’Amico DJ, Masonson HN, Patel M et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology113(6), 992–1001, e1006 (2006).
   PubMed Web of Science ®Google Scholar
• Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology114(9), 1702–1712 (2007).
   PubMed Web of Science ®Google Scholar
• Heier JS, Boyer DS, Ciulla TA et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch. Ophthalmol.124(11), 1532–1542 (2006).
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UM, PROTECT Study Group. Preliminary Results From an Open-Label, Multicenter, Phase II Study Assessing the Effects of Same-Day Andministration of Ranibizumab (Lucentis™) and Verteporfin PDT (PROTECT Study). Invest. Ophthalmol. Vis. Sci. Fort Lauderdale, FL, USA, ARVO E-Abstract 2960 (2006).
   Google Scholar
• Coleman AL, Yu F. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999. Ophthalmology115(1), 18–25 (2008).
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Brown HC, Kindermann S, Sharma S. A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration. Ophthalmology114(6), 1170–1178 (2007).
   PubMed Web of Science ®Google Scholar
• Smiddy WE. Relative cost of a line of vision in age-related macular degeneration. Ophthalmology114(5), 847–854 (2007).
   PubMed Web of Science ®Google Scholar
• Brown GC, Brown MM, Campanella J, Beauchamp GR. The cost-utility of photodynamic therapy in eyes with neovascular macular degeneration – a value-based reappraisal with 5-year data. Am. J. Ophthalmol.140(4), 679–687 (2005).
   PubMed Web of Science ®Google Scholar
• Berdugo M, Bejjani RA, Valamanesh F et al. Evaluation of the new photosensitizer stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest. Opthalmol. Vis. Sci.49(4), 1633–1644 (2008).
   PubMed Web of Science ®Google Scholar
• Seshadri M, Bellnier DA, Vaughan LA et al. Light delivery over extended time periods enhances the effectiveness of photodynamic therapy. Clin. Cancer Res.14(9), 2796–2805 (2008).
   PubMed Web of Science ®Google Scholar
• Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg. Med.38(5), 489–493 (2006).
   PubMed Web of Science ®Google Scholar
• Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest. Opthalmol. Vis. Sci.47(1), 371–376 (2006).
   PubMed Web of Science ®Google Scholar
• Sharman WM, van Lier JE, Allen CM. Targeted photodynamic therapy via receptor mediated delivery systems. Adv. Drug Deliv. Rev.56(1), 53–76 (2004).
   PubMed Web of Science ®Google Scholar
• Schneider R, Tirand L, Frochot C et al. Recent improvements in the use of synthetic peptides for a selective photodynamic therapy. Anticancer Agents Med. Chem.6(5), 469–488 (2006).
   PubMedGoogle Scholar
• Renno RZ, Terada Y, Haddadin MJ, Michaud NA, Gragoudas ES, Miller JW. Selective photodynamic therapy by targeted verteporfin delivery to experimental choroidal neovascularization mediated by a homing peptide to vascular endothelial growth factor receptor-2. Arch. Ophthalmol.122(7), 1002–1011 (2004).
   PubMed Web of Science ®Google Scholar
• Renno RZ, Miller JW. Photosensitizer delivery for photodynamic therapy of choroidal neovascularization. Adv. Drug Deliv. Rev.52(1), 63–78 (2001).
   PubMed Web of Science ®Google Scholar
• Tamaki Y. Novel approach for management of age-related macular degeneration – antiangiogenic therapy and retinal regenerative therapy. Nippon Ganka Gakkai zasshi111(3), 232–269 (2007).
   PubMedGoogle Scholar
• Dixon MJ, Bourre L, Macrobert AJ, Eggleston IM. Novel prodrug approach to photodynamic therapy: Fmoc solid-phase synthesis of a cell permeable peptide incorporating 5-aminolaevulinic acid. Bioorg. Med. Chem. Lett.17(16), 4518–4522 (2007).
   PubMed Web of Science ®Google Scholar